CardioPrecision Ltd, a Scottish technology company focussed on less invasive treatment of structural heart disease and cardiothoracic interventions, has received new investment from InnoScot Health and others

The equity financing was led by existing investors, principally London & Scottish Investment Partners, Discovery Investment Fund and Scottish Enterprise.

CardioPrecision was originally spun out of the NHS through InnoScot Health, and the organisation is pleased to also participate in this funding round for the first time since the spin out.

This bridging round of equity investment will allow CardioPrecision to begin roll out of its technology post relaxation of international COVID restrictions.

“CardioPrecision has a platform technology for advancing cardiovascular solutions with the potential to significantly improve outcomes for patients,” said Graham Watson, Executive Chair at InnoScot Health. “We are delighted to support the company and its management team as it pushes towards getting its lifesaving technology to market.”

Roshan Maini, Chairman of CardioPrecision, added: “We are delighted to receive investment from InnoScot Health, which has a track record of supporting healthcare innovation.”

Dr Ying Sutherland, CEO of CardioPrecision, commented: “We are grateful to all our investors for their continued confidence in the management team and the CoreVista® technology. The company is committed to delivering growth and increasing shareholder value.”

Kerry Sharp, Director of Entrepreneurship and Investment at Scottish Enterprise said: “Scotland is globally renowned for its strengths in life sciences because of its innovative companies, incredible talent and world-class universities. CardioPrecision is a great example of that strength in action, and we are pleased to continue our support for this early-stage exciting company breaking new ground in such an important field.”

Quest Corporate Ltd served as corporate financial advisor and Burness Paull LLP as legal advisor to CardioPrecision Ltd.